RFWD3 and central nervous system cancer: Lomitapide, an FDA‐approved lipid‐lowering drug, has been shown to prevent tumor cell growth and enhance therapeutic efficacy in multiple myeloma and glioma.[24, 25] To confirm the interaction between lomitapide and RFWD3, we performed drug affinity responsive target stability (DARTS) and cell thermal shift assays (CETSA).